Monday, September 21, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchglp-1 receptor agonistsbreast cancer surgeryperioperative safety

Surgery journal questions 30-day morbidity as GLP-1 safety yardstick

Tambasco and colleagues argue the standard 30-day window may not capture the surgical risks of GLP-1 receptor agonists in breast cancer patients.

PR
By Priya Raman · Science Reporter
Sep 19 20:00 ETSource: World journal of surgery

The wire

  1. 01A World Journal of Surgery paper published 20 September 2026 by Tambasco, Tomaselli, Albanese and colleagues examines whether 30-day morbidity adequately defines surgical safety for patients on GLP-1 receptor agonists undergoing breast cancer surgery.
  2. 02Perioperative teams increasingly face patients on incretin therapy, where delayed gastric emptying and wound-healing questions bear on anesthesia and reconstruction planning.
  3. 03Only the title and authorship are available; the underlying data, patient numbers and any recommended perioperative interval are not detailed here.

From the source

GLP-1 Receptor Agonists and Breast Cancer Surgery: Is 30-Day Morbidity Enough to Define Surgical Safety?

World journal of surgery · 2026 Sep 20 · Tambasco D, Tomaselli F, Albanese R et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42764534/